Biological Assembly 1  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors.

Macromolecule Content

• Total Structure Weight: 32.94 kDa 
• Atom Count: 2,407 
• Modelled Residue Count: 271 
• Deposited Residue Count: 279 
• Unique protein chains: 1

 1QPE

STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS

• PDB DOI:  https://doi.org/10.2210/pdb1QPE/pdb

• Classification: TRANSFERASE
• Organism(s): Homo sapiens
• Expression System: Trichoplusia ni
• Mutation(s): Yes 


• Deposited: 1999-05-24 Released: 2000-05-31 
• Deposition Author(s): Zhu, X., Morgenstern, K.A.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.00 Å
• R-Value Free: 0.254 
• R-Value Work: 0.189 
• R-Value Observed: 0.189 

Literature

Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors.

Zhu, X., Kim, J.L., Newcomb, J.R., Rose, P.E., Stover, D.R., Toledo, L.M., Zhao, H., Morgenstern, K.A.

(1999) Structure 7: 651-661

• PubMed: 10404594 
• DOI: https://doi.org/10.1016/s0969-2126(99)80086-0
• Primary Citation of Related Structures:  
  1QPC, 1QPD, 1QPE, 1QPJ


• PubMed Abstract: 
  

The lymphocyte-specific kinase Lck is a member of the Src family of non-receptor tyrosine kinases. Lck catalyzes the initial phosphorylation of T-cell receptor components that is necessary for signal transduction and T-cell activation. On the basis of both biochemical and genetic studies, Lck is considered an attractive cell-specific target for the design of novel T-cell immunosuppressants. To date, the lack of detailed structural information on the mode of inhibitor binding to Lck has limited the discovery of novel Lck inhibitors.

---

Organizational Affiliation: 

Kinetix Pharmaceuticals, Inc., Medford, MA 02155, USA. [e-mail]

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
LCK KINASE	A	279	Homo sapiens	Mutation(s): 1  Gene Names: LCK EC: 2.7.1.112 (PDB Primary Data), 2.7.10.2 (UniProt)
UniProt & NIH Common Fund Data Resources
Find proteins for P06239 (Homo sapiens) Explore P06239  Go to UniProtKB:  P06239
PHAROS:  P06239

Small Molecules

Ligands 2 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
PP2	E [auth A]	1-TERT-BUTYL-3-(4-CHLORO-PHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-YLAMINE C15 H17 Cl N5 PBBRWFOVCUAONR-UHFFFAOYSA-O
SO4	B [auth A], C [auth A], D [auth A]	SULFATE ION O4 S QAOWNCQODCNURD-UHFFFAOYSA-L

Modified Residues  1 Unique
ID	Chains	Type	Formula	2D Diagram	Parent
PTR	A	L-PEPTIDE LINKING	C9 H12 N O6 P		TYR

Binding Affinity Annotations
ID	Source	Binding Affinity
PTR	BindingDB:  1QPE	Kd: 4.00e+5 (nM) from 1 assay(s)
PP2	Binding MOAD:  1QPE	IC50: 20 (nM) from 1 assay(s)
	PDBBind:  1QPE	IC50: 20 (nM) from 1 assay(s)

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.00 Å
• R-Value Free: 0.254 
• R-Value Work: 0.189 
• R-Value Observed: 0.189 
• Space Group: P 2₁ 2₁ 2₁

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 42.5	α = 90
b = 74.09	β = 90
c = 91.98	γ = 90

Software Package:

Software Name	Purpose
AMoRE	phasing
X-PLOR	refinement
DENZO	data reduction
SCALEPACK	data scaling

Structure Validation

Entry History 

Deposition Data

• Released Date: 2000-05-31 
Deposition Author(s): Zhu, X., Morgenstern, K.A.

Revision History  

• Version 1.0: 2000-05-31
  Type: Initial release
  
• Version 1.1: 2008-04-27
  Changes: Version format compliance
• Version 1.2: 2011-07-13
  Changes: Version format compliance